Bing Xiang

Area of research

Pathology and Forensic Medicine · Genetics

Research interest

Research focused on Diffuse large B-cell lymphoma and Oncology, with related work in Hepatocellular carcinoma, Discontinuation, Clinical endpoint. Notable publications include 'Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma', 'Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: Results from a phase II, single-arm, multicenter, study', and '1470O Perioperative camrelizumab plus rivoceranib in resectable hepatocellular carcinoma (CARES-009): A randomized, multicenter, phase III trial'.

h-index

—

citations

works

NIH funding

—

primary concept

—

✉ Find email ↗

Recent publications

1470O Perioperative camrelizumab plus rivoceranib in resectable hepatocellular carcinoma (CARES-009): A randomized, multicenter, phase III trial

Annals of Oncology 2025cited by 0position: middledoi

Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma

Blood Advances 2021cited by 47position: middledoi

Zanubrutinib monotherapy for patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma: Results from a phase II, single-arm, multicenter, study.

Journal of Clinical Oncology 2020cited by 6position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Looking for a research collaborator?

Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.

Find collaborators in Pathology and Forensic Medicine · Genetics →